Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Bullish +72

Agilent Technologies (A) Stock Could Be 21.1% Undervalued After Earnings Beat And Higher Outlook - simplywall.st

📈 Agilent Technologies beat Q2 2026 earnings expectations and raised its full-year revenue outlook.

💰 The stock price surged 14.91% over the last 30 days following the positive earnings report.

🏭 Strategic growth is driven by high-margin recurring revenue streams including consumables, software, and services.

🌍 The company announced plans to open a new China Innovation Center to expand its global footprint.

🤝 Agilent completed or advanced its acquisition of Biocare to strengthen its portfolio.

💵 Analysts calculate a fair value of $161.00, implying the stock is currently 21.1% undervalued at $127.06.

📊 The current P/E ratio of 25.4x is slightly above the estimated fair ratio of 22.6x but below peer averages.

🛡️ Agilent maintains a flawless balance sheet and continues to pay a dividend to shareholders.

⚠️ Potential risks include tariff-related cost pressures affecting margins in international markets.

🏛️ Funding constraints in the academic and government sectors could impact future demand for diagnostics.

Bullish Signals
  • Agilent Technologies beat Q2 2026 earnings expectations, demonstrating strong operational performance.
  • The company raised its full-year revenue outlook, signaling confidence in future growth trajectories.
  • Strategic focus on recurring revenue streams like CrossLab and services is delivering consistent mid-single-digit growth.
  • High customer satisfaction rates indicate a stable and expanding installed base for consumables and software.
  • The stock has gained 14.91% in the last 30 days, reflecting immediate market appreciation of the earnings beat.
  • Analyst fair value models suggest the stock is undervalued by 21.1%, trading well below the $161.00 target price.
  • The company possesses a flawless balance sheet, providing financial flexibility for future investments or acquisitions.
  • Agilent pays a dividend, offering income support alongside capital appreciation potential.
Risk Factors
  • Tariff-related cost pressures could increase operating expenses and compress profit margins in the near term.
  • Potential funding constraints within the academic and government sectors may limit demand for certain diagnostic solutions.
  • The current P/E ratio of 25.4x is higher than the estimated fair ratio of 22.6x, suggesting some premium pricing.
Full Analysis
Agilent Technologies (A) reported strong Q2 2026 revenue growth, beating earnings expectations and raising its full-year outlook. The company is also advancing strategic initiatives including the establishment of a China Innovation Center and the acquisition of Biocare. Following these positive results, Agilent's share price has rallied with a 30-day return of 14.91%, though it remains down 7.89% year-to-date. Analysts suggest the stock is currently undervalued by approximately 21.1%, trading at $127.06 against a calculated fair value of $161.00 based on a 7.94% discount rate. The bullish narrative relies on a shift toward higher-margin recurring revenue streams, specifically consumables, software, services, and digital platforms like CrossLab, which are driving mid-single-digit growth. However, investors must weigh these gains against potential headwinds such as tariff-related cost pressures and funding constraints within the academic and government sectors. Valuation metrics show a mixed picture where the current P/E ratio of 25.4x is slightly above the estimated fair ratio of 22.6x but remains lower than peer averages in the Life Sciences sector. The company maintains a flawless balance sheet and pays a dividend, supporting its status as a high-quality investment despite the valuation premium.